SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma

Autor: Adalbert Krawczyk, Hannes Klump, Marianne Breyer, Veronika Lenz, Laura Thümmler, Lukas van de Sand, Peter A. Horn, Sebastian Dolff, Monika Lindemann, Leonie Schipper, Oliver Witzke, Margarethe Konik, Dietmar Knop, Maximillian Platte, Hana Rohn, Christian Temme, Sina Schwarzkopf, Ulf Dittmer, Maren Bormann
Rok vydání: 2021
Předmět:
Cellular immunity
Enzyme-Linked Immunospot Assay
medicine.medical_treatment
Medizin
Antibodies
Viral
Immunoglobulin G
0302 clinical medicine
030212 general & internal medicine
Kidney transplantation
Research Articles
Aged
80 and over
Immunity
Cellular
hemodialysis
biology
ELISPOT
Middle Aged
Infectious Diseases
C-Reactive Protein
Spike Glycoprotein
Coronavirus
convalescent plasma
030211 gastroenterology & hepatology
Female
Hemodialysis
Antibody
Viral load
Research Article
ELISpot
kidney transplantation
cellular immunity
Antiviral Agents
03 medical and health sciences
Renal Dialysis
COVID‐19
Virology
medicine
Humans
COVID-19 Serotherapy
Aged
business.industry
SARS-CoV-2
Immunization
Passive
COVID-19
medicine.disease
Antibodies
Neutralizing
Immunity
Humoral
COVID-19 Drug Treatment
Immunology
biology.protein
business
Kidney disease
Zdroj: Journal of Medical Virology
ISSN: 1096-9071
Popis: When patients with chronic kidney disease are infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) they can face two specific problems: virus‐specific immune responses may be impaired and remdesivir, an antiviral drug described to shorten recovery, is contraindicated. Antiviral treatment with convalescent plasma (CP) could be an alternative treatment option. In this case report, we present two kidney transplant recipients and two hemodialysis patients who were infected with SARS‐CoV‐2 and received CP. Antibodies against the receptor‐binding domain in the S1 subunit of the SARS‐CoV‐2 spike protein were determined sequentially by immunoglobulin G (IgG) enzyme‐linked immunosorbent assay (ELISA) and neutralization assay and specific cellular responses by interferon‐gamma ELISpot. Before treatment, in both kidney transplant recipients and one hemodialysis patient antibodies were undetectable by ELISA (ratio
Highlights After treatment with convalescent plasma we observed an increase of specific humoral and cellular immunity in two kidney transplant recipients and two haemodialysis patients with SARS‐CoV‐2 infection.However, the success of convalescent plasma therapy was only be temporary in one transplant recipient.Short‐term monitoring of viral load and antiviral immunity appears as mandatory for this patient group.
Databáze: OpenAIRE
Externí odkaz: